VivoSeq
Other

Mydriasis

6

Pipeline Programs↗

0

Active Trials↗

8

Companies Involved↗

Mydriasis is an early-stage landscape with 6 programs across 8 companies. The most active players are Sanofi, Advanz Pharma, Viatris Specialty LLC. 3 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

29/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

92/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sanofi logo

Sanofi

1 program

Phase 1A

Advanz Pharma

1 program

Phase 1V

Viatris Specialty LLC

1 program

Phase 1O

Ocuphire Pharma, Inc.

1 program

Phase 3F

Fresenius Kabi Oncology Ltd.

1 program

ApprovedE

Exela Pharma Sciences, LLC.

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

13

clinical trials

Completed11 · 85%
Terminated1 · 8%
Unknown status1 · 8%

Clinical Trials

Trial Activity

13 trials

Comparison Mydriasis by Mydrane With Topical Drop Application
Completed·MMedical University of Graz·Phase 4·NCT04880928·42 enrolled
Comparison of Instillation and Packing in Mydriasis for Premature Infants
Completed·KKhon Kaen University·Phase 4·NCT00877175·25 enrolled
Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)
Completed·OOcuphire Pharma, Inc.·Phase 3·NCT05134974·368 enrolled
2.5% and 10% Phenylephrine for Mydriasis in Diabetic Patients With Darkly Pigmented Irides
Completed·KKhon Kaen University·Phase 4·NCT00501878·100 enrolled
Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis
Completed·OOcuphire Pharma, Inc.·Phase 3·NCT04620213·185 enrolled
Changes in Vital Signs and Pupil Diameter Related to Pharmacologic Mydriasis in Premature Infants: A Randomized Double Blind Clinical Study
Completed·UUniversity of the Philippines·Phase 4·NCT04838665·60 enrolled
Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects
Completed·OOcuphire Pharma, Inc.·Phase 3·NCT05223478·23 enrolled
Study on Effective Mydriasis in Premature Infants
Completed·GGeorgetown University·N/A·NCT01054027·15 enrolled
Study to Assess the Influence of Three Different α-antagonists and Placebo on the Extent of Weekly Phenylephrine-induced Mydriasis at Three Different Concentrations of Phenylephrine in Healthy Male Volunteers
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT02266537·97 enrolled
Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis
Completed·OOcuphire Pharma, Inc.·Phase 2·NCT04024891·32 enrolled
Lidocaine Usage for Pupil Dilatation (Mydriasis)
Completed·—·N/A·NCT01170130·100 enrolled
Optimal Method for Mydriasis in Cataract Surgery
Terminated·JJohns Hopkins University·N/A·NCT02909140·3 enrolled
Effect of Anti-inflammatory Topical Prednisolone, Nepafenac and Ketorolac in Intra-operative Mydriasis in Facetectomies
Unknown status·CClinica Oftamologica Zona Sul·Phase 4·NCT00865540·30 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)